| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA153: Entecavir for the treatment of chronic hepatitis B |
|
Medicine details |
|
| Medicine name | entecavir (Baraclude®) |
| Formulation | film-coated tablet |
| Reference number | 126 |
| Indication | Treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Infections |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/03/2007 |
| NICE guidance | |